WASHINGTON, Oct. 13 (Xinhua) -- U.S. drugmaker Eli Lilly said Tuesday it has paused its trial of a combination antibody treatment for COVID-19 for safety reasons.
The company said the trial's Data Safety Monitoring Board (DSMB), an independent group of medical experts who monitor clinical trials, recommended the pause.
Already a subscriber? Log in.
Limited time offer:
Just RM5 per month.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!